Gainers
Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
Major Wall Street indices closed in the green on Thursday after investors and traders questioned the possibility of continued aggression by the Federal Reserve following the release of joble
Pharvaris NV (NASDAQ:PHVS) announced topline data from the RAPIDe-1 Phase 2 study, demonstrating statistically significant results of PHVS416 as an oral…